Interactions between psychotropics, anaesthetics and electroconvulsive therapy: Implications for drug choice and patient management

CNS Drugs

Volumn 16, Issue 4, 2002, Pages 229-247

  Naguib, Mohamed ^a   Koorn, Robert ^a  

^a UNIVERSITY OF IOWA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANESTHETIC AGENT; ANTIARRHYTHMIC AGENT; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ANTIPYRETIC ANALGESIC AGENT; ANXIOLYTIC AGENT; BARBITURIC ACID DERIVATIVE; BENZODIAZEPINE DERIVATIVE; CARBAMAZEPINE; FLUOXETINE; LEVODOPA; LITHIUM; METHYLDOPA; MIANSERIN; MIRTAZAPINE; MONOAMINE OXIDASE INHIBITOR; NEFAZODONE; NEUROLEPTIC AGENT; NEUROMUSCULAR BLOCKING AGENT; PROPOFOL; PSYCHOTROPIC AGENT; REBOXETINE; SEROTONIN UPTAKE INHIBITOR; TRAZODONE; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG; VALPROATE SEMISODIUM; VALPROIC ACID; VASODILATOR AGENT; VENLAFAXINE;

ANESTHESIA; ANTICONVULSANT ACTIVITY; BIPOLAR DEPRESSION; DOSE RESPONSE; DRUG CHOICE; DRUG CLASSIFICATION; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; ELECTROCONVULSIVE THERAPY; HUMAN; HYPERTENSION; PHARMACODYNAMICS; PRIORITY JOURNAL; PSYCHOPHARMACOLOGY; PSYCHOPHARMACOTHERAPY; REVIEW; SCHIZOPHRENIA; SEIZURE;

EID: 0036245971     PISSN: 11727047     EISSN: None     Source Type: Journal    
DOI: 10.2165/00023210-200216040-00003     Document Type: Review

References (196)

1. A survey of attitudes on the use of electroconvulsive therapy
2. ECT: An assessment of mental health professionals' knowledge and attitudes
3. Characteristics of psychiatrists who perform ECT
4. Use of ECT in the United States in 1975, 1980, and 1986
5. Use of electroconvulsive therapy in the Medicare population between 1987 and 1992
6. Diagnoses of patients treated with ECT: A comparison of evidence-based standards with reported use
7. Electroconvulsive therapy in the treatment of depression: The impact on length of stay
8. Use of ECT for the inpatient treatment of recurrent major depression
9. Use of ECT in California, 1977-1983
10. Incidence of asystole in electroconvulsive therapy in elderly patients
11. Postictal pulmonary edema
12. Splenic rupture after electroconvulsive therapy
13. Subtypes of memory dysfunction associated with ECT: Characteristics and neurobiological bases
14. Prescribing trends in psychotropic medications: Primary care, psychiatry, and other medical specialities
15. Epidemiology of prescriptions for neuroleptic drugs: Tranquilizers rather than antipsychotics
16. Trends in prescribing psychotropic medications
17. Psychotropic drug prescription patterns among patients with bipolar I disorder
18. Effect of lidocaine on seizure discharge in electroconvulsive therapy
19. Seizure duration and clinical effect in electroconvulsive therapy
20. Factors affecting amnesia, seizure duration, and efficacy in ECT
21. Minimizing therapeutic differences between bilateral and unilateral nondominant ECT
22. Effects of stimulus intensity and electrode placement on the efficacy and cognitive effects of electroconvulsive therapy
23. The effects of ECT stimulus dose and electrode placement on the ictal electroencephalogram: An intraindividual crossover study
24. EEG manifestations during ECT: Effects of electrode placement and stimulus intensity
25. ECT seizure therapeutic adequacy
26. The postictal electroencephalogram
27. Is postictal electrical silence a predictor of response to electroconvulsive therapy?
28. Increased seizure duration during ECT with trazodone administration
29. Electroconvulsive therapy in a depressed patient receiving bupropion
30. Seizures and bupropion: A review
31. Caffeine-modified electroconvulsive therapy in depressed patients with medical illness
32. Anesthetic induction for ECT with etomidate is associated with longer seizure duration than thiopentone
33. Propofol and methohexital as anesthetic agents for electroconvulsive therapy (ECT): A comparison of seizure-quality measures and vital signs
34. Propofol anaesthesia in electroconvulsive therapy: Reduced seizure duration may not be relevant
35. Comparison of methohexital and propofol for electroconvulsive therapy: Effects on hemodynamic responses and seizure duration
36. Recovery after electroconvulsive therapy: Comparison of propofol with methohexitone anaesthesia
37. Clinically significant drug interactions with general anaesthetics: Incidence, mechanisms and management
38. Inhibition and induction of cytochrome P450 and the clinical implications
39. P450 superfamily: Update on new sequences, gene mapping, accession numbers and nomenclature
40. Interindividual variability in inhibition and induction of cytochrome P450 enzymes
41. Action of various antidepressant treatments reduces reactivity of noradrenergic cyclic AMP-generating system in limbic forebrain
42. The mechanism of action of antidepressants revised
43. The serotonergic and noradrenergic systems of the hippocampus: Their interactions and the effects of antidepressant treatments
44. Neuropsychopharmacology and the affective disorders (first of three parts)
45. Neuropsychopharmacology and the affective disorders (second of three parts)
46. Cardiac complications of tricyclic antidepressant therapy
47. Brain 5-HT1C receptors and antidepressants
48. Clinical effects of the 5-HT1A partial agonists in depression: A composite analysis of buspirone in the treatment of depression
49. A randomized, within-patient, cross-over, placebo-controlled trial on the efficacy and tolerability of the tricyclic antidepressants chlorimipramine and nortriptyline in central pain
50. Blockade of cardiac sodium channels by amitriptyline and diphenylhydantoin: Evidence for two use-dependent binding sites
51. Inhibition of neuronal Na+ channels by antidepressant drugs
52. Imipramine's selective suppression of an L-type calcium channel in neurons of murine dorsal root ganglia involves G proteins
53. Antidepressant-induced lipidosis with special reference to tricyclic compounds
54. Cardiovascular effects of tricyclic antidepressants in depressed patients with chronic heart disease
55. Cardiovascular effects of antidepressant medications
56. Cardiovascular complications of ECT in depressed patients with cardiac disease
57. Cardiac responses to imipramine and pancuronium during anesthesia with halothane or enflurane
58. Volatile anesthetics and tricyclic antidepressives. A case study
59. Treatment of unipolar depression following electroconvulsive therapy. Relapse rate comparisons between lithium and tricyclic therapies following ECT
60. Efficacy and safety of combined ECT and tricyclic antidepressant drugs in the treatment of depressed psychiatric patients
61. Immunocytochemical localization of monoamine oxidases A and B in human peripheral tissues and brain
62. Molecular basis of human MAO A and B
63. Some observations upon a new inhibitor of monoamine oxidase in brain tissue
64. Some puzzling pharmacological effects of monoamine oxidase inhibitors
65. Age-related changes on MAO in B1/C57 mouse tissues: A quantitative radioautographic study
66. The present status of monoamine oxidase inhibitors
67. A survey of prescribing practices for monoamine oxidase inhibitors
68. Neurochemical profile of moclobemide, a short-acting and reversible inhibitor of monoamine oxidase type A
69. Reversible and selective inhibitors of monoamine oxidase A in the treatment of depressed elderly patients
70. Barbiturate intoxication in a patient with a MAO inhibiton
71. Psychotropic drugs (2). Interaction between monoamine oxidase (MAO) inhibitors and other substances
72. MAOIs to RIMAs in anaesthesia a literature review
73. Interaction studies with moclobemide
74. Monoamine oxidase inhibitors: Should they be discontinued preoperatively?
75. Monoamine oxidase inhibitors and anaesthesia: A review
76. The spectrum of behaviors influenced by serotonin
77. Selective serotonin reuptake inhibitors in affective disorders - I. Basic pharmacology
78. A review of central 5-HT receptors and their function
79. Effect of 1-(m-chlorophenyl)piperazine and 1-(m- trifluoromethylphenyl)piperazine on locomotor activity
80. Antidepressant-like behavioral effects mediated by 5-hydroxytryptamine(2C) receptors
81. Evidence for a role of 5-HT1C receptors in the antiserotonergic properties of some antidepressant drugs
82. Antidepressant drug interactions and the cytochrome P450 system: A critical appraisal
83. Antidepressant drug interactions and the cytochrome P450 system: The role of cytochrome P450 2D6
84. Fluoxetine and ECT
85. Does fluoxetine prolong electrically induced seizures?
86. Electroconvulsive therapy and fluoxetine
87. The combined use of bupropion, lithium, and venlafaxine during ECT: A case of prolonged seizure activity
88. Effects of lithium treatment and its discontinuation on suicidal behavior in bipolar manic-depressive disorders
89. Clinical pharmacokinetics of lithium
90. Lithium in the treatment of mood disorders
91. A molecular mechanism for the effect of lithium on development
92. Neural and developmental actions of lithium: A unifying hypothesis
93. Toward a crystal-clear view of lithium's site of action
94. Signal transduction pathways: Molecular targets for lithium's actions
95. Activation of the Wnt signaling pathway: A molecular mechanism for lithium action
96. Lithium inhibits glycogen synthase kinase-3 activity and mimics wingless signalling in intact cells
97. Molecular mechanisms underlying mood stabilization in manic-depressive illness: The phenotype challenge
98. The mood-stabilizing agents lithium and valproate robustly increase the levels of the neuroprotective protein bcl-2 in the CNS
99. The myoneural effects of lithium chloride on the nerve-muscle preparations of rats: Role of adenosine triphosphate-sensitive potassium channels
100. Potentiation of succinylcholine neuromuscular blockade by lithium carbonate
101. Lithium carbonate and neuromuscular blocking agents
102. Prolongation of muscle relaxant effects by lithium carbonate
103. Potential hazards and applications of lithium in anesthesiology
104. The use of pancuronium bromide in patients receiving lithium carbonate
105. Clinical significance of the interaction between lithium and a neuromuscular blocker
106. Propofol, seizure and antidepressants
107. Lithium and maintenance ECT
108. Lithium interactions: Lithium and electroconvulsive therapy
109. Response to lithium carbonate
110. Treatment of unipolar depression following electroconvulsive therapy: Relapse rate comparisons between lithium and tricyclics therapies following ECT
111. Recent advances in treatment of acute mania
112. Efficacy of divalproex vs lithium and placebo in the treatment of mania
113. Changes in use of valproate and other mood stabilizers for patients with schizophrenia from 1994 to 1998
114. Sodium valproate enhancement of gamma-aminobutyric acid (GABA) inhibition: Electrophysiological evidence for anticonvulsant activity
115. A double-blind comparison of valproate and lithium in the treatment of acute mania
116. Inhibition of uptake, steady-state currents, and transient charge movements generated by the neuronal GABA transporter by various anticonvulsant drugs
117. The mood-stabilizing agent valproate inhibits the activity of glycogen synthase kinase-3
118. Interaction between thiopentone and sodium valproate: An in vitro and in vivo study
119. In vitro neuromuscular effects of valproic acid
120. Carbamazepine decreases catecholamine turnover in the rat brain
121. Metabolism of carbamazepine
122. Comparative effects of carbamazepine and carbamazepine-10,11-epoxide on hepatic cytochromes P450 in the rat
123. Phenytoin reduces frequency potentiation of synaptic potentials at the frog neuromuscular junction
124. On the mechanism by which phenytoin blocks post-tetanic potentiation at the frog neuromuscular junction
125. Chronic carbamazepine therapy does not influence mivacurium-induced neuromuscular block
126. Atracurium-induced neuromuscular block is not affected by chronic anticonvulsant therapy with carbamazepine
127. Resistance to pancuronium in patients receiving carbamazepine
128. Accelerated recovery from doxacurium-induced neuromuscular blockade in patients receiving chronic anticonvulsant therapy
129. Influence of carbamazepine on the dose-response relationship of vecuronium
130. Pharmacokinetic origin of carbamazepine-induced resistance to vecuronium neuromuscular blockade in anesthetized patients
131. Decreased sensitivity to metocurine during long-term phenytoin therapy may be attributable to protein binding and acetylcholine receptor changes
132. Prolonged duration of succinylcholine in patients receiving anticonvulsants: Evidence for mild up-regulation of acetylcholine receptors?
133. An in vitro investigation of the action of lamotrigine on neuronal voltage-activated sodium channels
134. Pharmacological studies on lamotrigine, a novel potential antiepileptic drug: II. Neurochemical studies on the mechanism of action
135. Enzyme induction and inhibition by new anti-epileptic drugs: A review of human studies
136. The combined effects of halothane and lamotrigine on excitatory postsynaptic potentials and use-dependent block in the rat dentate gyms in vitro
137. A summary of mechanistic hypotheses of gabapentin pharmacology
138. Characterisation of [3H]gabapentin binding to a novel site in rat brain: Homogenate binding studies
139. The novel anticonvulsant drug, gabapentin (Neurontin), binds to the alpha2delta subunit of a calcium channel
140. Topiramate enhances GABA-mediated chloride flux and GABA-evoked chloride currents in murine brain neurons and increases seizure threshold
141. Clinical significance of animal seizure models and mechanism of action studies of potential antiepileptic drugs
142. Topiramate: Preclinical evaluation of structurally novel anticonvulsant
143. Nephrolithiasis on topiramate therapy
144. Does fast dissociation from the dopamine D(2) receptor explain the action of atypical antipsychotics? A new hypothesis
145. d-Amphetamine-induced depression of central dopamine neurons: Evidence for mediation by both autoreceptors and a striato-nigral feedback pathway
146. Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs
147. Effect of haloperidol on cyclic AMP and inositol triphosphate in rat striatum in vivo
148. Loss of hatoperidol induced gene expression and catalepsy in protein kinase A-deficient mice
149. Subtype-selective inhibition of N-methyl-D-aspartate receptors by haloperidol
150. Atypical antipsychotics: New directions and new challenges in the treatment of schizophrenia
151. Clinical and theoretical implications of 5-HT2 and D2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia
152. Potent antagonism of 5-HT(3) and 5-HT(6) receptors by olanzapine
153. Atypical antipsychotics in the treatment of schizophrenia: Systematic overview and meta-regression analysis
154. Adverse psychotropic drug-drug interactions
155. Hypotension and cardiopulmonary arrest associated with concurrent haloperidol and propranolol therapy
156. Propranolol in schizophrenia: II. Clinical and biochemical aspects of combining propranolol with chlorpromazine
157. Effect of pindolol administration on serum levels of thioridazine, haloperidol, phenytoin, and phenobarbital
158. Antipsychotic drugs and heart muscle disorder in international pharmacovigilance: Data mining study
159. Effect of antipsychotic drugs on human liver cytochrome P-450 (CYP) isoforms in vitro: Preferential inhibition of CYP2D6
160. Combined use of ECT and psychotropic drugs: Antidepressives and antipsychotics
161. The combined use of neuroleptics and ECT in drug resistant schizophrenic patients
162. Electric convulsive therapy (ECT) increases plasma and red blood cell haloperidol neuroleptic activities
163. Benzodiazepine recognition sites on GABA receptors
164. Insights into the structure and function of GABA-benzodiazepine receptors: Ion channels and psychiatry
165. Evidence for less improvement in depression in patients taking benzodiazepines during unilateral ECT
166. Midazolamthiopental anesthetic interaction in patients
167. Propofol and midazolam act synergistically in combination
168. In vivo induction and in vitro inhibition of hepatic cytochrome P450 activity by the benzodiazepine anticonvulsants clonazepam and diazepam
169. Myorelaxant effect of diazepam. Interactions with neuromuscular blocking agents and cholinergic drugs
170. Selectivity of release of norepinephrine, dopamine and 5-hydroxytryptamine by amphetamine in various regions of rat brain
171. Prediction of reinforcing responses to psychostimulants in humans by brain dopamine D2 receptor levels
172. Randomized trial of modafinil as a treatment for the excessive daytime somnolence of narcolepsy: US Modafinil in Narcolepsy Multicenter Study Group
173. Postoperative effects of methylphenidate
174. Short-term cardiovascular effects of methylphenidate and adderall
175. Calcium antagonists in mania: A double-blind study of verapamil
176. Adverse interaction between nifedipine and beta-blockade
177. Drug interactions with calcium channel blockers: Possible involvement of metabolite-intermediate complexation with CYP3A
178. Cardiac ion channels
179. Potentiation of neuromuscular blockade by verapamil
180. The effects of verapamil and diltiazem pretreatment on potassium release in dogs after the administration of succinylcholine
181. How does pindolol improve antidepressant action?
182. Cardiogenic shock after electroconvulsive therapy
183. Prevention of the cardiovascular and neuroendocrine response to electroconvulsive therapy: I. Effectiveness of pretreatment regimens on hemodynamics
184. Comparison of two esmolol bolus doses on the haemodynamic response and seizure duration during electroconvulsive therapy
185. Low-dose esmolol bolus reduces seizure duration during electroconvulsive therapy: A double-blind, placebo-controlled study
186. A hypothesis of thyroid-catecholamine-receptor interaction: Its relevance to affective illness
187. Hypothyroidism and depression: A therapeutic challenge
188. Thyroid hormone treatment of primary unipolar depression: A review
189. Routine screening of thyroid function in patients hospitalized for major depression or dysthymia?
190. Estrogen therapy and aggressive behavior in elderly patients with moderate-to-severe dementia: Results from a short-term, randomized, doubleblind trial
191. Effects of chronic estrogen treatment on dopamine concentrations and turnover in discrete brain nuclei of ovariectomized rats
192. An animal model for the effects of estradiol on dopamine-mediated behavior: Implications for sex differences in schizophrenia
193. Age-associated testosterone decline in men: Clinical issues for psychiatry
194. Dopamine receptors - Physiological understanding to therapeutic intervention potential
195. Pergolide-induced hypotension